Comments
Loading...

AtriCure Analyst Ratings

ATRCNASDAQ
Logo brought to you by Benzinga Data
$31.31
-1.61-4.89%
At close: -
$31.31
0.000.00%
After Hours: 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$75.00
Lowest Price Target1
$40.00
Consensus Price Target1
$51.67

AtriCure Analyst Ratings and Price Targets | NASDAQ:ATRC | Benzinga

AtriCure Inc has a consensus price target of $51.67 based on the ratings of 12 analysts. The high is $75 issued by SVB Leerink on May 4, 2022. The low is $40 issued by JP Morgan on October 30, 2024. The 3 most-recent analyst ratings were released by Citizens Capital Markets, Canaccord Genuity, and JP Morgan on April 2, 2025, March 28, 2025, and March 27, 2025, respectively. With an average price target of $52.67 between Citizens Capital Markets, Canaccord Genuity, and JP Morgan, there's an implied 68.21% upside for AtriCure Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Jan
6
Feb
4
Mar
0
0
0
0
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.4
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Citizens Capital Markets
Canaccord Genuity
JP Morgan
Needham
Oppenheimer

1calculated from analyst ratings

Analyst Ratings for AtriCure

Buy NowGet Alert
04/02/2025Buy Now91.63%Citizens Capital Markets
Daniel Stauder36%
$60 → $60ReiteratesMarket Outperform → Market OutperformGet Alert
03/28/2025Buy Now66.08%Canaccord Genuity
William Plovanic57%
$66 → $52MaintainsBuyGet Alert
03/27/2025Buy Now46.92%JP Morgan
Lilia-Celine Lozada29%
$51 → $46MaintainsOverweightGet Alert
03/27/2025Buy Now62.89%Needham
Mike Matson57%
$51 → $51ReiteratesBuy → BuyGet Alert
03/21/2025Buy Now62.89%Needham
Mike Matson57%
$51 → $51ReiteratesBuy → BuyGet Alert
02/13/2025Buy Now43.72%Oppenheimer
Suraj Kalia53%
$36 → $45MaintainsOutperformGet Alert
02/13/2025Buy Now59.69%Piper Sandler
Matt O'Brien51%
$40 → $50MaintainsOverweightGet Alert
02/13/2025Buy Now91.63%JMP Securities
Daniel Stauder36%
$60 → $60ReiteratesMarket Outperform → Market OutperformGet Alert
02/13/2025Buy Now53.31%Stifel
Rick Wise74%
$36 → $48MaintainsBuyGet Alert
02/13/2025Buy Now62.89%Needham
Mike Matson57%
$51 → $51ReiteratesBuy → BuyGet Alert
02/13/2025Buy Now110.8%Canaccord Genuity
William Plovanic57%
$61 → $66MaintainsBuyGet Alert
02/11/2025Buy Now62.89%JP Morgan
Lilia-Celine Lozada29%
$40 → $51MaintainsOverweightGet Alert
02/10/2025Buy Now91.63%JMP Securities
Daniel Stauder36%
$60 → $60ReiteratesMarket Outperform → Market OutperformGet Alert
01/22/2025Buy Now62.89%Needham
Mike Matson57%
$40 → $51MaintainsBuyGet Alert
01/13/2025Buy Now27.75%Needham
Mike Matson57%
$40 → $40ReiteratesBuy → BuyGet Alert
12/17/2024Buy Now27.75%JP Morgan
Lilia-Celine Lozada29%
→ $40Assumes → OverweightGet Alert
12/09/2024Buy Now94.83%Canaccord Genuity
William Plovanic57%
$53 → $61MaintainsBuyGet Alert
10/30/2024Buy Now69.27%Canaccord Genuity
William Plovanic57%
$49 → $53MaintainsBuyGet Alert
10/30/2024Buy Now14.98%Oppenheimer
Suraj Kalia53%
$32 → $36MaintainsOutperformGet Alert
10/30/2024Buy Now27.75%JP Morgan
Robbie Marcus67%
$30 → $40MaintainsOverweightGet Alert
10/30/2024Buy Now27.75%UBS
Danielle Antalffy57%
$35 → $40MaintainsBuyGet Alert
10/30/2024Buy Now27.75%Needham
Mike Matson57%
$34 → $40MaintainsBuyGet Alert
07/31/2024Buy Now69.27%BTIG
Marie Thibault63%
$58 → $53MaintainsBuyGet Alert
07/31/2024Buy Now-4.18%JP Morgan
Robbie Marcus67%
$34 → $30MaintainsOverweightGet Alert
07/31/2024Buy Now-16.96%Stifel
Rick Wise74%
$30 → $26MaintainsBuyGet Alert
07/31/2024Buy Now27.75%Piper Sandler
Matt O'Brien51%
$65 → $40MaintainsOverweightGet Alert
07/31/2024Buy Now8.59%Needham
Mike Matson57%
$40 → $34MaintainsBuyGet Alert
07/08/2024Buy Now27.75%Needham
Mike Matson57%
$40 → $40ReiteratesBuy → BuyGet Alert
05/02/2024Buy Now56.5%Canaccord Genuity
William Plovanic57%
$57 → $49MaintainsBuyGet Alert
05/02/2024Buy Now8.59%JP Morgan
Robbie Marcus67%
$42 → $34MaintainsOverweightGet Alert
05/02/2024Buy Now27.75%Needham
Mike Matson57%
$46 → $40MaintainsBuyGet Alert
04/23/2024Buy Now2.2%Oppenheimer
Suraj Kalia53%
→ $32UpgradePerform → OutperformGet Alert
04/10/2024Buy Now46.92%Needham
Mike Matson57%
$46 → $46ReiteratesBuy → BuyGet Alert
02/16/2024Buy Now85.24%UBS
Danielle Antalffy57%
$57 → $58MaintainsBuyGet Alert
02/16/2024Buy Now34.14%Stifel
Rick Wise74%
$50 → $42MaintainsBuyGet Alert
02/16/2024Buy Now46.92%Needham
Mike Matson57%
$44 → $46MaintainsBuyGet Alert
01/22/2024Buy Now82.05%UBS
Danielle Antalffy57%
$56 → $57MaintainsBuyGet Alert
01/04/2024Buy Now40.53%Needham
Mike Matson57%
$49 → $44MaintainsBuyGet Alert
11/29/2023Buy Now91.63%JMP Securities
Daniel Stauder36%
→ $60ReiteratesMarket Outperform → Market OutperformGet Alert
11/29/2023Buy Now56.5%Needham
Mike Matson57%
→ $49ReiteratesBuy → BuyGet Alert
11/02/2023Buy Now59.69%JP Morgan
Robbie Marcus67%
$60 → $50MaintainsOverweightGet Alert
11/02/2023Buy Now56.5%Needham
Mike Matson57%
$68 → $49MaintainsBuyGet Alert
10/23/2023Buy Now91.63%JMP Securities
Daniel Stauder36%
→ $60Initiates → Market OutperformGet Alert
09/29/2023Buy Now78.86%UBS
Danielle Antalffy57%
→ $56Initiates → BuyGet Alert
07/26/2023Buy Now117.18%Needham
Mike Matson57%
$60 → $68MaintainsBuyGet Alert
06/02/2023Buy Now91.63%Needham
Mike Matson57%
→ $60ReiteratesBuy → BuyGet Alert
05/03/2023Buy Now91.63%Needham
Mike Matson57%
$58 → $60MaintainsBuyGet Alert
04/17/2023Buy Now85.24%Needham
Mike Matson57%
→ $58MaintainsBuyGet Alert
02/22/2023Buy Now75.66%BTIG
Marie Thibault63%
$65 → $55MaintainsBuyGet Alert
02/22/2023Buy Now53.31%Stifel
Rick Wise74%
$55 → $48MaintainsBuyGet Alert
02/22/2023Buy Now136.35%Canaccord Genuity
William Plovanic57%
$81 → $74MaintainsBuyGet Alert
02/22/2023Buy Now85.24%Needham
Mike Matson57%
→ $58Reiterates → BuyGet Alert
02/06/2023Buy Now158.7%Canaccord Genuity
William Plovanic57%
$67 → $81MaintainsBuyGet Alert
12/19/2022Buy Now85.24%Needham
Mike Matson57%
$55 → $58MaintainsBuyGet Alert
11/02/2022Buy Now107.6%Canaccord Genuity
William Plovanic57%
$72 → $65MaintainsBuyGet Alert
11/02/2022Buy Now75.66%Needham
Mike Matson57%
$65 → $55MaintainsBuyGet Alert
10/17/2022Buy Now126.76%BTIG
Marie Thibault63%
$75 → $71MaintainsBuyGet Alert
08/03/2022Buy Now75.66%Piper Sandler
Matt O'Brien51%
$90 → $55MaintainsOverweightGet Alert
08/03/2022Buy Now107.6%Needham
Mike Matson57%
$55 → $65MaintainsBuyGet Alert
07/18/2022Buy Now59.69%Stifel
Rick Wise74%
$70 → $50MaintainsBuyGet Alert
06/28/2022Buy Now75.66%Needham
Mike Matson57%
$67 → $55MaintainsBuyGet Alert
06/24/2022Buy Now139.54%BTIG
Marie Thibault63%
$94 → $75MaintainsBuyGet Alert
05/04/2022Buy Now113.99%Needham
Mike Matson57%
$79 → $67MaintainsBuyGet Alert
05/04/2022Buy Now139.54%SVB Leerink
Danielle Antalffy57%
$95 → $75MaintainsOutperformGet Alert

FAQ

Q

What is the target price for AtriCure (ATRC) stock?

A

The latest price target for AtriCure (NASDAQ:ATRC) was reported by Citizens Capital Markets on April 2, 2025. The analyst firm set a price target for $60.00 expecting ATRC to rise to within 12 months (a possible 91.63% upside). 33 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for AtriCure (ATRC)?

A

The latest analyst rating for AtriCure (NASDAQ:ATRC) was provided by Citizens Capital Markets, and AtriCure reiterated their market outperform rating.

Q

When was the last upgrade for AtriCure (ATRC)?

A

The last upgrade for AtriCure Inc happened on April 23, 2024 when Oppenheimer raised their price target to $32. Oppenheimer previously had a perform for AtriCure Inc.

Q

When was the last downgrade for AtriCure (ATRC)?

A

There is no last downgrade for AtriCure.

Q

When is the next analyst rating going to be posted or updated for AtriCure (ATRC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AtriCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AtriCure was filed on April 2, 2025 so you should expect the next rating to be made available sometime around April 2, 2026.

Q

Is the Analyst Rating AtriCure (ATRC) correct?

A

While ratings are subjective and will change, the latest AtriCure (ATRC) rating was a reiterated with a price target of $60.00 to $60.00. The current price AtriCure (ATRC) is trading at is $31.31, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch